Cargando…

Adalimumab (Humira) induced acute lung injury

PATIENT: Male, 78 FINAL DIAGNOSIS: Acute lung injury due to Adalimumab SYMPTOMS: — MEDICATION: Adalimumab CLINICAL PROCEDURE: Intubated and put on mechanical ventilation SPECIALTY: Pulmonology OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: Adalimumab is a recombinant human monoclon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohli, Ritesh, Namek, Karim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700490/ https://www.ncbi.nlm.nih.gov/pubmed/23826460 http://dx.doi.org/10.12659/AJCR.889200

Ejemplares similares

Adalimumab (Humira™) in Ophthalmology: A Review of the Literature
por: Neri, Piergiorgio, et al.
Publicado: (2010)

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)
por: Tebbey, Paul W, et al.
Publicado: (2015)

Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
por: Magnenat, Laurent, et al.
Publicado: (2016)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
por: Zhang, Erhui, et al.
Publicado: (2020)

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
por: Kwon, Joon-Cheol, et al.
Publicado: (2021)

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects
por: Hyland, Elizabeth, et al.
Publicado: (2016)

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects
por: Hillson, Jan, et al.
Publicado: (2018)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
por: Vural, Sevilay, et al.
Publicado: (2022)

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
por: Van den Bosch, Filip, et al.
Publicado: (2017)

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
por: Van den Bosch, Filip, et al.
Publicado: (2017)

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy
por: Sinha, Shubhadeep, et al.
Publicado: (2020)

A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis
por: Jani, Rajendrakumar H., et al.
Publicado: (2015)

Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations
por: Kaneko, Kayoko, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
por: Su, Jinmei, et al.
Publicado: (2020)

Design and Evaluation of a Multiplexed Assay to Assess Human Immunogenicity Against Humira®
por: Alleyn, Matthew, et al.
Publicado: (2020)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Is adalimumab protective in ischemia-reperfusion injury in lung?
por: Kurt, Aysel, et al.
Publicado: (2015)

Antiinflammatory effects of adalimumab, tocilizumab, and steroid on lipopolysaccharide-induced lung injury
por: SARIOĞLU, Nurhan, et al.
Publicado: (2021)

Pretreatment with adalimumab reduces ventilator-induced lung injury in an experimental model
por: Correger, Enrique, et al.
Publicado: (2020)

Clinical Evaluation of Humira(®) Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
por: Dillingh, Marlous R., et al.
Publicado: (2016)

Adalimumab induced interstitial lung disease
por: Aqsa, Anum, et al.
Publicado: (2020)

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
por: Cohen, Stanley B, et al.
Publicado: (2018)

Similar Pharmacokinetics of the Adalimumab (Humira(®)) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE(®)-AI and VOLTAIRE(®)-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials
por: Ramael, Steven, et al.
Publicado: (2018)

A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program
por: Karlsdottir, Kristin, et al.
Publicado: (2022)

Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis
por: Dias, Olívia Meira, et al.
Publicado: (2014)

Extravascular Lung Water and Acute Lung Injury
por: Maharaj, Ritesh
Publicado: (2012)

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
por: Jamshidi, Ahmadreza, et al.
Publicado: (2017)

Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
por: Lénon, Marine, et al.
Publicado: (2020)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Adalimumab induced pulmonary sarcoid reaction
por: Bhargava, S., et al.
Publicado: (2013)

Adalimumab Ameliorates Abdominal Aorta Cross Clamping Which Induced Liver Injury in Rats
por: Cure, Erkan, et al.
Publicado: (2014)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Anti-Thymocyte Globulin Induced Acute Lung Injury in a Case of Renal Allograft Recipient
por: Gupta, Nimish, et al.
Publicado: (2021)

Drug-Induced Liver Injury Caused by Adalimumab: A Case Report and Review of the Bibliography
por: Frider, Bernardo, et al.
Publicado: (2013)

The effects of intravitreal adalimumab injection on pseudophakic macular edema
por: Farvardin, Mohsen, et al.
Publicado: (2020)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment
por: Yoon, Ji Ha, et al.
Publicado: (2022)

Favorable efficacy of adalimumab treatment in experimental acute pancreatitis model
por: ÇAKIR GÜNEY, Başak, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gg17qljegm80ocvrfap78i86b1